Insmed (INSM) Misses Q1 EPS by 4c ; Offers Guidance
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $124.89 -1.11%
Revenue Growth %: +253.1%
Financial Fact:
Operating loss: -37.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +253.1%
Financial Fact:
Operating loss: -37.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q1 EPS of ($1.17), $0.04 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.93 million.
GUIDANCE:
Insmed sees FY2023 revenue of $285-300 million, versus the consensus of $293 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- CBRE Global Real Estate Income Fund adjusts September distribution after split
- GameStop beats second quarter estimates on collectibles
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
